Lower dose of intravenous immunoglobulin (I.V.IG) results in comparable outcome in children with newly diagnosed ITP
Main Authors: | Vineetha Raghavan, Chandran K. Nair, Anju R. Kurup |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-01-01
|
Series: | Pediatric Hematology Oncology Journal |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2468124516300559 |
Similar Items
-
Study on the Treatment of ITP Mice with IVIG Sourced from Distinct Sex-Special Plasma (DSP-IVIG)
by: Wei Zhang, et al.
Published: (2023-11-01) -
Absence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG).
by: Julia Kostka, et al.
Published: (2024-03-01) -
Intravenous immunoglobulins (IVIG) in severe/critical COVID-19 adult patients
by: Dorota Kwapisz, et al.
Published: (2023-07-01) -
Injection of intravenous immunoglobulin (IVIg) for the treatment of Coronavirus induced cytokine storm
by: Farahnoosh Farnood, et al.
Published: (2022-12-01) -
Retreatment with intravenous immunoglobulin (IVIG) of refractory Guillain Barre syndrome in children
by: Rivas Larrauri Francisco, et al.
Published: (2014-07-01)